We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Elevated Gene Expression Correlates with Prostate Cancer Severity

By LabMedica International staff writers
Posted on 10 Sep 2018
Elevated expression of the gene ANO7 has been shown to correlate with the severity and possible outcome of prostate cancer (PrCa).

Based on earlier studies showing that genetic signals at 2q37, the location of the prostate specific ANO7 gene were indicators of likelihood of developing prostate cancer, investigators at the University of Turku, Finland) focused on this gene as part of their effort to find germline biomarkers that could predict outcome of the disease.

To investigate, in detail, the associations between the ANO7 gene and PrCa risk and disease aggressiveness, ANO7 from castration resistant tumors was sequenced together with samples from unselected PrCa patients and unaffected males. More...
Two pathogenic variants were discovered and genotyped in 1769 patients and 1711 unaffected males.

Variant rs77559646 showed both risk and association with aggressive PrCa, while high ANO7 expression was independently linked to poor survival. ANO7 genotypes correlated with expression and biochemical relapse, suggesting that ANO7 was a potential PrCa susceptibility gene and that its elevated expression correlated with disease severity and outcome.

"We found that small genetic changes to the ANO7 gene increase a patient's risk of aggressive prostate cancer. One of the current biggest unmet needs in prostate cancer care is being able to diagnose aggressive cancers at an early stage. Genetic testing for ANO7 could help identify these patients sooner and may bring new opportunities for precision oncology in prostate cancer," said senior author Dr. Johanna Schleutker, professor of biomedicine of the University of Turku.

The study was published in the August 29, 2018, online edition of the International Journal of Cancer.

Related Links:
University of Turku


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.